SS
RLMD icon

SBI Securities’s Relmada Therapeutics RLMD Stock Holding History

SBI Securities’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35 Sell
5
-36
-88% -$252 ﹤0.01% 3749
2026
Q1 		$285 Sell
41
-16
-28% -$76 ﹤0.01% 3094
2025
Q4 		$275 Sell
57
-45
-44% -$151 ﹤0.01% 3107
2025
Q3 		$205 Hold
102
– – ﹤0.01% 3311
2025
Q2 		$61 Hold
102
– – ﹤0.01% 3678
2025
Q1 		$28 Hold
102
– – ﹤0.01% 3787
2024
Q4 		$53 Buy
+102
New +$249 ﹤0.01% 3628

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SBI Securities's RLMD Position: Q2 2026 in Review

SBI Securities reduced its Relmada Therapeutics (RLMD) stake by 88% in Q2 2026, selling an estimated $252 and leaving 5 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

SBI Securities first reported a position in RLMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $285 in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • SBI Securities held 5 shares of Relmada Therapeutics worth $35 as of Q2 2026.
  • SBI Securities sold 36 Relmada Therapeutics shares in Q2 2026, an estimated $252.
  • Relmada Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3749 holding.
  • SBI Securities first reported a position in Relmada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Relmada Therapeutics position peaked at $285 in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.